Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
6.74
+0.33 (5.23%)
At close: Mar 9, 2026, 4:00 PM EDT
6.54
-0.20 (-2.90%)
After-hours: Mar 9, 2026, 7:18 PM EDT
Aptevo Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 7 | 2 | 3 | 11 | 37 | 150 | |
| Market Cap Growth | 34.41% | -36.51% | -68.79% | -70.52% | -75.46% | 460.07% | |
| Enterprise Value | -10 | -0 | -10 | -1 | 4 | 154 | |
| Last Close Price | 6.74 | 1551.60 | 106077.48 | 1359667.12 | 4612319.05 | 21479224.05 | |
| PE Ratio | - | - | - | 1.36 | - | - | |
| PS Ratio | - | - | - | 3.49 | 3.00 | 34.89 | |
| PB Ratio | 0.30 | 0.45 | 0.28 | 0.61 | 30.34 | 9.06 | |
| P/TBV Ratio | 0.39 | 0.45 | 0.28 | 0.61 | 30.34 | 9.06 | |
| EV/Sales Ratio | - | - | - | - | 0.34 | 35.68 | |
| Debt / Equity Ratio | 0.28 | 1.14 | 0.44 | 0.55 | 13.75 | 1.65 | |
| Net Debt / Equity Ratio | -0.94 | -0.70 | -0.94 | -0.70 | -23.30 | -0.76 | |
| Net Debt / EBITDA Ratio | 0.62 | 0.14 | 0.41 | 0.46 | 1.40 | 0.48 | |
| Net Debt / FCF Ratio | 0.62 | 0.14 | 0.98 | 0.60 | 1.26 | 0.43 | |
| Asset Turnover | - | - | - | 0.07 | 0.22 | 0.08 | |
| Quick Ratio | 3.75 | 1.40 | 2.34 | 2.89 | 1.40 | 2.91 | |
| Current Ratio | 4.03 | 1.72 | 2.64 | 3.15 | 1.51 | 3.25 | |
| Return on Equity (ROE) | -242.74% | -284.28% | -123.53% | 73.10% | -330.24% | -217.49% | |
| Return on Assets (ROA) | -79.19% | -76.06% | -61.12% | -39.42% | -24.29% | -32.13% | |
| Return on Capital Employed (ROCE) | -124.90% | -262.20% | -163.90% | -112.30% | -98.00% | -70.50% | |
| Earnings Yield | -415.93% | -1119.63% | -512.92% | 73.80% | -77.12% | -11.80% | |
| FCF Yield | -388.59% | -1103.63% | -345.56% | -193.53% | -60.69% | -19.56% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.